You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Research Articles
Popular Research Articles
Highly Recommended Research Articles
Send a link to this page to your friends and colleagues.
Living Cells Technologies (LCT) has announced that their Moscow trial of pig cell implantation, which began in June, is well underway: In September, the second of six type 1 patients was injected with 5,000 "islet equivalents per kilogram" of Diabecells into the peritoneal cavity.
The Russian patients will receive their second dose of the alginate-encapsulated porcine beta cells six months after the first.
Both patients are doing well. The first patient has been able to cut his insulin requirement by 39 percent, and the second has been weaned completely off injected insulin. This is good news for LCT, which recently got a promise of up to $9.8 million in investment money from a United States group. LCT hopes that New Zealand authorities will allow them to begin another set of clinical trials in New Zealand before Christmas.
This trial will involve eight long-standing type 1s who will receive higher doses of Diabecells than the Russian patients. LCT has met all the regulatory requirements and obtained the necessary ethics approvals, so are just waiting for permission to go forward from the New Zealand Ministry of Health. Based upon those approvals, their stock recently soared three cents.
* * *
Sources: Stuff.co.nz; the Age Company, Ltd, October 2007; LCT press release
0 comments - Nov 14, 2007
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.